TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives Average Recommendation of “Hold” from Analysts

Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) have been assigned a consensus rating of “Hold” from the five brokerages that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $11.00.

TLSI has been the subject of several recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of TriSalus Life Sciences in a research note on Monday, December 15th. Zacks Research upgraded TriSalus Life Sciences from a “strong sell” rating to a “hold” rating in a research note on Tuesday, December 16th. Wall Street Zen upgraded TriSalus Life Sciences from a “sell” rating to a “hold” rating in a research note on Friday, November 28th. Finally, Canaccord Genuity Group increased their price target on TriSalus Life Sciences from $11.00 to $12.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th.

TriSalus Life Sciences Trading Down 2.7%

NASDAQ TLSI opened at $6.87 on Monday. TriSalus Life Sciences has a 12 month low of $3.42 and a 12 month high of $7.95. The stock has a 50 day moving average of $5.82 and a 200-day moving average of $5.15. The company has a market cap of $343.23 million, a PE ratio of -3.40 and a beta of 0.42.

TriSalus Life Sciences (NASDAQ:TLSI) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.79). The business had revenue of $11.57 million for the quarter, compared to analysts’ expectations of $11.76 million. As a group, sell-side analysts predict that TriSalus Life Sciences will post -1.55 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Nantahala Capital Management LLC acquired a new position in shares of TriSalus Life Sciences in the second quarter valued at approximately $10,900,000. AWM Investment Company Inc. acquired a new stake in TriSalus Life Sciences during the 2nd quarter worth approximately $6,812,000. Vanguard Group Inc. boosted its stake in TriSalus Life Sciences by 42.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,159,575 shares of the company’s stock valued at $5,392,000 after purchasing an additional 345,186 shares during the period. Gilder Gagnon Howe & Co. LLC grew its holdings in TriSalus Life Sciences by 32.1% in the 2nd quarter. Gilder Gagnon Howe & Co. LLC now owns 1,092,975 shares of the company’s stock valued at $5,957,000 after buying an additional 265,618 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in TriSalus Life Sciences by 107.4% during the 2nd quarter. Geode Capital Management LLC now owns 455,051 shares of the company’s stock worth $2,480,000 after buying an additional 235,627 shares during the period. 2.58% of the stock is owned by institutional investors.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.